August 6, 2020 -- Contract research organizations (CROs) Caprion-HistoGeneX and Viroclinics have formed a strategic partnership to develop therapeutics and prophylactic solutions targeting infectious diseases like COVID-19.
Through the partnership, the companies will leverage their respective expertise in contract research serving the pharmaceutical and biotechnology communities to offer a full suite of specialized services to support vaccine and antiviral clinical and preclinical studies. This will include research sites in the Netherlands, Canada, U.S., Belgium, U.K., Australia, and China.
The companies will provide an integrated service experience for customers with services covering all aspects of vaccine and antiviral development. This includes preclinical and in vitro research models to deployment of custom-developed and off-the-shelf functional efficacy assays. The partnership will also extend global access to clinical sample processing facilities with operational and logistical services included in sample management and sampling kits.